2seventy bio’s (TSVT) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of 2seventy bio (NASDAQ:TSVT) in a research note published on Friday,Weiss Ratings reports.

2seventy bio Stock Performance

NASDAQ:TSVT opened at $2.66 on Friday. The company has a fifty day moving average of $2.60 and a two-hundred day moving average of $3.70. The stock has a market capitalization of $137.22 million, a PE ratio of -1.43 and a beta of 1.73. 2seventy bio has a fifty-two week low of $2.29 and a fifty-two week high of $5.99.

Institutional Investors Weigh In On 2seventy bio

Hedge funds have recently modified their holdings of the business. Erste Asset Management GmbH acquired a new stake in shares of 2seventy bio in the third quarter valued at about $25,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of 2seventy bio in the fourth quarter valued at about $32,000. BNP Paribas Financial Markets acquired a new stake in shares of 2seventy bio in the fourth quarter valued at about $35,000. ProShare Advisors LLC acquired a new stake in shares of 2seventy bio in the fourth quarter valued at about $48,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of 2seventy bio in the fourth quarter valued at about $52,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.